News

The randomized, controlled, blinded, cross-over study is designed to evaluate the safety and efficacy of FLX-787, the Company’s single molecule, chemically synthesized, transient receptor potential (TRP) ion channel

If approved, Carbylan will be renamed KalVista Pharmaceuticals, Inc. The transaction has been unanimously approved by the boards of directors of both companies. Carbylan’s three largest shareholders, InterWest

The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 and RGX-202, as well as further development of its therapeutics pipeline. "We are thrilled to have

This is the first program to enter clinical testing out of the discovery collaboration between the two companies. The molecule being advanced in clinical testing was discovered by

Existing investors Forbion Capital Partners, Edmond de Rothschild Investment Partners, EMBL Ventures and Allecra’s co-Founder Nicholas Benedict also participated in the round. Allecra will use the proceeds for

Kamada and Baxalta (formerly Baxter International’s BioScience business and now part of Shire) entered into a cooperation agreement in 2010 for the distribution and license of Glassia, which

HT-1 is a rare genetic disease in infants and children. It could lead to liver and kidney complications and become fatal if not treated. Orfadin is indicated as

The lead investigator of the double-blind placebo-controlled Phase II study is Dr. Tim Wigal. Dr. Wigal has been author or co-author of over 125 peer-reviewed articles about ADHD

The application was filed after the completion of the pre-clinical phase and proof-of-concept of the entourage technology and further to the Company’s preparations towards the development of a